Vertex to present data demonstrating significant benefits of long-term and early treatment with cftr modulators at the european cystic fibrosis conference

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced that five scientific abstracts on the company's portfolio of cystic fibrosis (cf) medicines will be presented at the european cystic fibrosis society's (ecfs) 45th european cystic fibrosis conference held june 8-11, 2022, in rotterdam, the netherlands. vertex will present the first analysis of data collected in the u.s. cf foundation patient registry (cffpr) of over 16,000 people with cf treated with tri
VRTX Ratings Summary
VRTX Quant Ranking